Strong join forces! Roche and Dean's diagnosis have partnered with tumor gene sequencing.

On April 27, Roche, an internationally renowned pharmaceutical company, announced that Roche and its holding company Foundation Medicine had signed a technical authorization agreement with Dean Diagnostics for Comprehensive Genomic Sequencing Analysis (CGP). According to the agreement, Dean's diagnosis will become the sole partner of the technology in the Chinese market, jointly promoting new standards of individualized tumor medicine and improving the overall efficiency of tumor diagnosis and treatment.
the "Healthy China 2030" Outline of Planning, clearly requires that by 2030, China's overall five-year cancer survival rate should be further improved by 15%. According to the latest data released by the National Cancer Center in 2018, about 278 people per 100,000 people have been diagnosed with new cases and about 167 have died of cancer;
Roche made personalized healthcare a core strategy of the Group as early as 2006 and took over Foundation Medicine in 2015 to accelerate research and development in the field of molecular information. FoundationOne ® is the first product to be launched in this partnership and the first comprehensive genome sequencing analysis service for patients with solid tumors in China. Patients need only one test to obtain a comprehensive genome map analysis report. This report will provide clinicians with comprehensive molecular information about their treatment decisions and identify more treatment options to help develop more targeted clinical treatment sourcing.
it is understood that the results of peer-reviewed validation of the genome sequencing analysis methods and technology platforms used by Foundation Medicine have been published in Nature Biotechnology, the world's leading scientific journal, and has so far benefited more than 180,000 patients worldwide. Dean Diagnostics is expected to launch two more analytical molecular information products in 2019
®
FoundationOne
®
Heme and Foundation ACT
®
. (Ye Zhengxing)
.